hypertension
Cardiovascular · 2005–2013
26decisions
18medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| olmesartan medoxomil, amlodipine, hydrochlorothiazide Treatment of hypertension in patients whose blood pressure is not adequately controlled by two of the following: an angiotensin II receptor antagonist, a… | Jul 2013 | Recommended with restriction | no section in document |
| telmisartan with amlodipine Treatment of hypertension in patients not adequately controlled with either telmisartan or amlodipine monotherapy. | Mar 2011 | Recommended with restriction | no section in document |
| aliskiren Treatment of hypertension in patients where an agent acting on the renin-angiotensin system is clinically indicated. | Jul 2010 | Not recommended | no section in document |
| amlodipine / valsartan / hydrochlorothiazide Hypertension in patients not adequately controlled with any two of the drugs in the combination. | Jul 2010 | Recommended with restriction | no section in document |
| losartan Treatment of hypertension, alone or in combination with other antihypertensives; treatment of hypertensive type 2 diabetics with proteinuria (defined as… | Jul 2010 | Recommended | no section in document |
| olmesartan medoxomil with amlodipine Hypertension in patients who are not adequately controlled with either angiotensin II receptor antagonist or dihydropyridine calcium channel blocker… | Jul 2010 | Recommended with restriction | no section in document |
| aliskiren Treatment of hypertension. | Jul 2010 | Not recommended | no section in document |
| amlodipine, valsartan, hydrochlorothiazide Hypertension in patients who are not adequately controlled with any two of the drugs in the combination. | Jul 2010 | Recommended with restriction | no section in document |
| losartan Treatment of hypertension, alone or in combination with other antihypertensives. Also registered for treatment of hypertensive type 2 diabetics with… | Jul 2010 | Recommended | no section in document |
| olmesartan medoxomil with amlodipine Hypertension in patients who are not adequately controlled with either angiotensin II receptor antagonist or dihydropyridine calcium channel blocker… | Jul 2010 | Recommended with restriction | no section in document |
| perindopril arginine with amlodipine besylate Substitution therapy in patients stabilised on treatment with perindopril and amlodipine given concurrently at the same dose level for hypertension and/or… | Mar 2010 | Recommended with restriction | no section in document |
| valsartan with hydrochlorothiazide Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy. | Jul 2008 | Recommended with restriction | no section in document |
| amlodipine besylate with valsartan Hypertension in patients who are not adequately controlled with either amlodipine or valsartan monotherapy. | Jul 2008 | Recommended with restriction | no section in document |
| lercanidipine with enalapril Hypertension in patients who are not adequately controlled with either lercanidipine or enalapril monotherapy. | Mar 2008 | Recommended with restriction | no section in document |
| ramipril with felodipine Treatment of hypertension in patients not adequately controlled with either ramipril or felodipine monotherapy, or who are receiving ramipril and felodipine… | Mar 2007 | Recommended with restriction | no section in document |
| olmesartan medoxomil with hydrochlorothiazide Treatment of hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan monotherapy. | Mar 2007 | Recommended with restriction | no section in document |
| ramipril with felodipine Treatment of hypertension in patients not adequately controlled with either ramipril or felodipine monotherapy, or who are receiving ramipril and felodipine… | Mar 2007 | Recommended with restriction | no section in document |
| amlodipine besylate with atorvastatin calcium Fixed combination for patients with concomitant hypertension and/or angina and dyslipidaemia who meet criteria for lipid-lowering therapy. | Jul 2006 | Recommended with restriction | no section in document |
| moxonidine Treatment of hypertension as add-on therapy in patients receiving concurrent antihypertensive therapy, where a centrally acting agent is required. | Mar 2006 | Recommended with restriction | no section in document |
| moxonidine Treatment of hypertension as add-on therapy in patients receiving concurrent antihypertensive therapy, where a centrally acting agent is required, and as an… | Mar 2006 | Recommended with restriction | no section in document |
| trandolapril with verapamil hydrochloride-SR Treatment of hypertension in patients who are not adequately controlled with 4 mg of trandolapril monotherapy. | Nov 2006 | Recommended with restriction | no section in document |
| trandolapril with verapamil hydrochloride-SR Treatment of hypertension in patients who are not adequately controlled with 4 mg of trandolapril monotherapy. | Nov 2006 | Recommended with restriction | no section in document |
| olmesartan medoxomil Treatment of hypertension. | Nov 2005 | Recommended | no section in document |
| trandolapril with verapamil hydrochloride Treatment of hypertension in patients already stabilised on concomitant trandolapril and verapamil therapy. Treatment should not be initiated with this fixed… | Nov 2005 | Not recommended | no section in document |
| olmesartan medoxomil Treatment of hypertension in adults. | Nov 2005 | Recommended | no section in document |
| trandolapril with verapamil hydrochloride Treatment of hypertension. Treatment should not be initiated with this fixed dose combination. | Nov 2005 | Not recommended | no section in document |
What the PBS pays
$1,999M in government benefit over 2024–25, across 100,933,951 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| amlodipine with valsartan and hydrochlorothiazide | $326.1M |
| amlodipine besylate with valsartan | $281.7M |
| amlodipine (as besylate) with valsartan and hydrochlorothiazide | $240M |
| valsartan with hydrochlorothiazide | $240M |
| amlodipine besylate with atorvastatin calcium | $224.9M |
| olmesartan medoxomil, amlodipine, hydrochlorothiazide | $158.5M |
| telmisartan with amlodipine | $155.7M |
| olmesartan medoxomil with amlodipine | $111.6M |
| perindopril arginine with amlodipine besylate | $111.6M |
| olmesartan medoxomil with hydrochlorothiazide | $61.2M |
| ramipril with felodipine | $30.4M |
| lercanidipine with enalapril | $24.4M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| candesartan cilexetilADESAN candesartan cilexetil 16 mg tablet blister pack | 1998 | 124 |
| metoprololAPO-METOPROLOL metoprolol tartrate 100 mg tablet blister pack | 1991 | 68 |
| carvedilolAPO-CARVEDILOL carvedilol 12.5 mg tablet blister pack | 1998 | 62 |
| atenololAPX-ATENOLOL atenolol 50mg tablet blister pack | 1993 | 56 |
| lisinoprilAPO- LISINOPRIL lisinopril 10 mg tablets bottle pack | 1999 | 47 |
| perindopril erbumineAPO-PERINDOPRIL perindopril erbumine 2mg tablets blister pack | 1992 | 38 |
| diltiazemAPO-DILTIAZEM CD diltiazem hydrochloride 180mg capsules blisterpack | 1993 | 22 |
| indapamide hemihydrateAPO-INDAPAMIDE SR indapamide hemihydrate 1.5 mg modified release table | 1993 | 14 |
| captoprilAPO-CAPTOPRIL 12.5mg tablet blister pack | 1991 | 10 |
| clonidineAPO-CLONIDINE clonidine hydrochloride 100 micrograms tablet bottle | 1991 | 8 |
| quinaprilGENRX QUINAPRIL TABLETS quinapril 20mg (as hydrochloride) tablets blis | 2006 | 8 |
| indapamide hemihydrate + perindopril erbumineAPO-PERINDOPRIL/INDAPAMIDE 4/1.25 perindopril erbumine/indapamide hemi | 2007 | 7 |
| spironolactoneAldactone 100mg tablet blister pack | 1993 | 6 |
| fosinoprilAPO-FOSINOPRIL fosinopril sodium 10mg tablet bottle | 2004 | 6 |
| prazosinAPO-PRAZOSIN prazosin (as hydrochloride) 1mg tablet blister pack | 1991 | 6 |
| nifedipineAPO-NIFEDIPINE XR nifedipine 30mg controlled release tablet blister pa | 2006 | 4 |
| clevidipineCLEVIPREX clevidipine, 25 mg in 50 mL injectable emulsion, Single Use | 2013 | 2 |
| indapamide + perindopril erbumineINDOPRIL COMBI 4/1.25 perindopril erbumine 4mg and indapamide hemihydr | 2009 | 2 |
| methyldopaALDOMET methyldopa (as sesquihydrate) 250 mg tablet bottle | 1991 | 2 |
| chlortalidoneHYGROTON 25 chlortalidone 25mg tablet bottle | 1991 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.